
<head>
<style>
.card {
  /* Add shadows to create the "card" effect */
  box-shadow: 0 4px 8px 0 rgba(0,0,0,0.2);
  transition: 0.3s;
  padding-left: 20px;
  padding-right: 20px;
  padding-top: 10px;
  padding-bottom: 10px;

}

.card-query {
    background: #EEEEFF;
    box-shadow: 0 0px 8px 0 rgba(0,0,0,0.2);
}

.button {
  background-color: #EEEEEE;
  border: none;
  color: black;
  padding: 15px 32px;
  text-align: center;
  text-decoration: none;
  display: inline-block;
  font-size: 16px;
}

</style>
</head>
<body style="margin-left: 10%; margin-right: 10%; padding-top: 70px;">
<div class="card card-query"><h2>Query: technology roadmap for diagnostics</h2><br /></div><br /><br /><br /><div class="card"><h3>Searching for the elusive typhoid diagnostic</h3>
<p style="text-align: justify; text-justify: inter-word;">Here we discuss the current position of typhoid diagnostics, highlight the need for technological improvements and suggest potential ways of advancing this area.</p>
<p align="right"><i>score: 203</i></p>

</div><br /><br /><br /><div class="card"><h3>MINIATURIZATION FOR POINT-OF-CARE ANALYSIS: PLATFORM TECHNOLOGY FOR ALMOST EVERY BIOMEDICAL ASSAY</h3>
<p style="text-align: justify; text-justify: inter-word;">Platform technologies for the changing need of diagnostics are one of the main challenges in medical device technology. From one point-of-view the demand for new and more versatile diagnostic is increasing due to a deeper knowledge of biomarkers and their combination with diseases. From another point-of-view a decentralization of diagnostics will occur since decisions can be made faster resulting in higher success of therapy. Hence, new types of technologies have to be established which enables a multiparameter analysis at the point-of-care. Within this review-like article a system called Fraunhofer ivD-platform is introduced. It consists of a credit-card sized cartridge with integrated reagents, sensors and pumps and a read-out/processing unit. Within the cartridge the assay runs fully automated within 15-20 minutes. Due to the open design of the platform different analyses such as antibody, serological or DNA-assays can be performed. Specific examples of these three different assay types are given to show the broad applicability of the system.</p>
<p align="right"><i>score: 188</i></p>

</div><br /><br /><br /><div class="card"><h3>Point-of-Care Device Design 1457 2. Inorganic Biomarkers of Infectious Diseases 1458 2.1. Hemozoin 1458 2.2. Iron in Schistosome Eggshells 1460 3. Metal-Based Sample Preparation 1461 3.1. Metal-Affinity Separation 1462 3.2. IMAC on Magnetic Particles 1463 4. Metal-Based Signal</h3>
<p style="text-align: justify; text-justify: inter-word;">Infectious diseases claim millions of lives each year. Robust and accurate diagnostics are essential tools for identifying those who are at risk and in need of treatment in low-resource settings. Inorganic complexes and metal-based nanomaterials continue to drive the development of diagnostic platforms and strategies that enable infectious disease detection in low-resource settings. In this review, we highlight works from the past 20 years in which inorganic chemistry and nanotechnology were implemented in each of the core components that make up a diagnostic test. First, we present how inorganic biomarkers and their properties are leveraged for infectious disease detection. In the following section, we detail metal-based technologies that have been employed for sample preparation and biomarker isolation from sample matrices. We then describe how inorganic-and nanomaterial-based probes have been utilized in point-ofcare diagnostics for signal generation. The following section discusses instrumentation for signal readout in resource-limited settings. Next, we highlight the detection of nucleic acids at the point of care as an emerging application of inorganic chemistry. Lastly, we consider the challenges that remain for translation of the aforementioned diagnostic platforms to low-resource settings.</p>
<p align="right"><i>score: 161</i></p>

</div><br /><br /><br /><div class="card"><h3>Advances in Directly Amplifying Nucleic Acids from Complex Samples</h3>
<p style="text-align: justify; text-justify: inter-word;">Advances in nucleic acid amplification technologies have revolutionized diagnostics for systemic, inherited, and infectious diseases. Current assays and platforms, however, often require lengthy experimental procedures and multiple instruments to remove contaminants and inhibitors from clinically-relevant, complex samples. This requirement of sample preparation has been a bottleneck for using nucleic acid amplification tests (NAATs) at the point of care (POC), though advances in "lab-on-chip" platforms that integrate sample preparation and NAATs have made great strides in this space. Alternatively, direct NAATs-techniques that minimize or even bypass sample preparation-present promising strategies for developing POC diagnostic tools for analyzing real-world samples. In this review, we discuss the current status of direct NAATs. Specifically, we surveyed potential testing systems published from 1989 to 2017, and analyzed their performances in terms of robustness, sensitivity, clinical relevance, and suitability for POC diagnostics. We introduce bubble plots to facilitate our analysis, as bubble plots enable effective visualization of the performances of these direct NAATs. Through our review, we hope to initiate an in-depth examination of direct NAATs and their potential for realizing POC diagnostics, and ultimately transformative technologies that can further enhance healthcare.</p>
<p align="right"><i>score: 155</i></p>

</div><br /><br /><br /><div class="card"><h3>(no title)</h3>
<p style="text-align: justify; text-justify: inter-word;">Recent years have seen unprecedented investment in research and development for countermeasures for high-threat pathogens, including specific and ambitious objectives for development of diagnostics, therapeutics, and vaccines. The inadequate availability of biological reference materials for these pathogens poses a genuine obstacle in pursuit of these objectives, and the lack of a comprehensive and equitable framework for developing reference materials is a weakness. We outline the need for internationally standardized biological materials for high-threat pathogens as a core element of global health security. We also outline the key components of a framework for addressing this deficiency.</p>
<p align="right"><i>score: 148</i></p>

</div><br /><br /><br /><div class="card"><h3>Developments in Transduction, Connectivity and AI/Machine Learning for Point-of-Care Testing</h3>
<p style="text-align: justify; text-justify: inter-word;">We review some emerging trends in transduction, connectivity and data analytics for Point-of-Care Testing (POCT) of infectious and non-communicable diseases. The patient need for POCT is described along with developments in portable diagnostics, specifically in respect of Lab-on-chip and microfluidic systems. We describe some novel electrochemical and photonic systems and the use of mobile phones in terms of hardware components and device connectivity for POCT. Developments in data analytics that are applicable for POCT are described with an overview of data structures and recent AI/Machine learning trends. The most important methodologies of machine learning, including deep learning methods, are summarised. The potential value of trends within POCT systems for clinical diagnostics within Lower Middle Income Countries (LMICs) and the Least Developed Countries (LDCs) are highlighted.</p>
<p align="right"><i>score: 147</i></p>

</div><br /><br /><br /><div class="card"><h3>Isothermal Amplification Methods for the Detection of Nucleic Acids in Microfluidic Devices</h3>
<p style="text-align: justify; text-justify: inter-word;">Diagnostic tools for biomolecular detection need to fulfill specific requirements in terms of sensitivity, selectivity and high-throughput in order to widen their applicability and to minimize the cost of the assay. The nucleic acid amplification is a key step in DNA detection assays. It contributes to improving the assay sensitivity by enabling the detection of a limited number of target molecules. The use of microfluidic devices to miniaturize amplification protocols reduces the required sample volume and the analysis times and offers new possibilities for the process automation and integration in one single device. The vast majority of miniaturized systems for nucleic acid analysis exploit the polymerase chain reaction (PCR) amplification method, which requires repeated cycles of three or two temperature-dependent steps during the amplification of the nucleic acid target sequence. In contrast, low temperature isothermal amplification methods have no need for thermal cycling thus requiring simplified microfluidic device features. Here, the use of miniaturized analysis systems using isothermal amplification reactions for the nucleic acid amplification will be discussed.</p>
<p align="right"><i>score: 146</i></p>

</div><br /><br /><br /><div class="card"><h3>Diagnosis of Parasitic Diseases: Old and New Approaches</h3>
<p style="text-align: justify; text-justify: inter-word;">Methods for the diagnosis of infectious diseases have stagnated in the last 20-30 years. Few major advances in clinical diagnostic testing have been made since the introduction of PCR, although new technologies are being investigated. Many tests that form the backbone of the "modern" microbiology laboratory are based on very old and labour-intensive technologies such as microscopy for malaria. Pressing needs include more rapid tests without sacrificing sensitivity, value-added tests, and point-of-care tests for both high-and low-resource settings. In recent years, research has been focused on alternative methods to improve the diagnosis of parasitic diseases. These include immunoassays, molecular-based approaches, and proteomics using mass spectrometry platforms technology. This review summarizes the progress in new approaches in parasite diagnosis and discusses some of the merits and disadvantages of these tests.</p>
<p align="right"><i>score: 143</i></p>

</div><br /><br /><br /><div class="card"><h3>A Simple, Inexpensive Device for Nucleic Acid Amplification without Electricity-Toward Instrument- Free Molecular Diagnostics in Low-Resource Settings</h3>
<p style="text-align: justify; text-justify: inter-word;">Conclusions/Significance: We demonstrate that an electricity-free heater based on exothermic chemical reactions and engineered phase change materials can successfully incubate isothermal NA amplification assays, and that the results of those assays are not significantly different from ones incubated in parallel in commercially available PCR instruments. These results clearly suggest the potential of the non-instrumented nucleic acid amplification (NINA) heater for molecular diagnostics in LRS. When combined with other innovations in development that eliminate power requirements for sample preparation, cold reagent storage, and readout, the NINA heater will comprise part of a kit that should enable electricity-free NA testing for many important analytes.</p>
<p align="right"><i>score: 140</i></p>

</div><br /><br /><br /><div class="card"><h3>Multiplex logic processing isothermal diagnostic assays for an evolving virus</h3>
<p style="text-align: justify; text-justify: inter-word;">While point-of-care (POC) diagnostic assays can be performed at or near the site of sample acquisition, they have for the most part been considered to be relatively simplistic tests that provide relatively little information to a clinician or public health worker. Familiar examples include electrochemical sensors for glucose, 1 or rapid immunoassays for metabolites such as human chorionic gonadotropin (the canonical pregnancy test), 2 and pathogens, either directly (influenza viruses) or via immune responses (antibodies against HIV-1/2). 3 The range of conditions and pathogens that could be tested for could likely be greatly expanded by developing POC diagnostics for nucleic acids 3 that would have greater sensitivity and accuracy. However, the current gold standard for molecular diagnostics, the quantitative polymerase chain reaction (qPCR), requires significant technical expertise and expensive and cumbersome equipment. Even portable instruments, such the Cepheid GeneXpert Omni, cost several thousand dollars and rely on expensive qPCR cartridge consumables for individual tests.</p>
<p align="right"><i>score: 138</i></p>

</div><br /><br /><br /><div class="card"><h3>vaccines Assay Challenges for Emerging Infectious Diseases: The Zika Experience</h3>
<p style="text-align: justify; text-justify: inter-word;">From the perspective of vaccine development, it is imperative to accurately diagnose target infections in order to exclude subjects with prior exposure from evaluations of vaccine effectiveness, to track incident infection during the course of a clinical trial and to differentiate immune reactions due to natural infections from responses that are vaccine related. When vaccine development is accelerated to a rapid pace in response to emerging infectious disease threats, the challenges to develop such diagnostic tools is even greater. This was observed through the recent expansion of Zika virus infections into the Western Hemisphere in 2014-2017. When initial Zika vaccine clinical trials were being designed and launched in response to the outbreak, there were no standardized sets of viral and immunological assays, and no approved diagnostic tests for Zika virus infection. The diagnosis of Zika virus infection is still an area of active research and development on many fronts. Here we review emerging infectious disease vaccine clinical assay development and trial execution with a special focus on the state of Zika virus clinical assays and diagnostics.</p>
<p align="right"><i>score: 138</i></p>

</div><br /><br /><br /><div class="card"><h3>Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein</h3>
<p style="text-align: justify; text-justify: inter-word;">Antibody fragments might represent a useful, effective, and low cost alternative to full-length antibodies in Ebola related capture and diagnostics applications.</p>
<p align="right"><i>score: 138</i></p>

</div><br /><br /><br /><div class="card"><h3>Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings</h3>
<p style="text-align: justify; text-justify: inter-word;">To cite: Mazzola LT, Kelly-Cirino C. Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings.</p>
<p align="right"><i>score: 134</i></p>

</div><br /><br /><br /><div class="card"><h3>A Simple, Inexpensive Device for Nucleic Acid Amplification without Electricity-Toward Instrument- Free Molecular Diagnostics in Low-Resource Settings</h3>
<p style="text-align: justify; text-justify: inter-word;">Background: Molecular assays targeted to nucleic acid (NA) markers are becoming increasingly important to medical diagnostics. However, these are typically confined to wealthy, developed countries; or, to the national reference laboratories of developing-world countries. There are many infectious diseases that are endemic in low-resource settings (LRS) where the lack of simple, instrument-free, NA diagnostic tests is a critical barrier to timely treatment. One of the primary barriers to the practicality and availability of NA assays in LRS has been the complexity and power requirements of polymerase chain reaction (PCR) instrumentation (another is sample preparation).</p>
<p align="right"><i>score: 133</i></p>

</div><br /><br /><br /><div class="card"><h3>Programmable low-cost DNA-based platform for viral RNA detection</h3>
<p style="text-align: justify; text-justify: inter-word;">Viral detection is critical for controlling disease spread and progression. Recent emerging threats including the Zika and Ebola virus outbreaks highlight the cost and difficulty in responding rapidly. In low-resource areas, a key obstacle is quick and accurate detection of viruses near the point of care. To address these challenges, we develop a platform for low-cost and rapid detection of viral RNA with DNA nanoswitches designed to mechanically reconfigure in response to specific viruses. Using Zika virus as a model system, we show non-enzymatic detection of viral RNA to the attomole level, with selective and multiplexed detection between related viruses and viral strains. For clinical-level sensitivity in biological fluids, we paired the assay with a sample preparation step using either RNA extraction or isothermal preamplification. Our assay can be performed with minimal or no lab infrastructure, and is readily adaptable (with ~24-hour development time) to detect other viruses. Given this versatility, we expect that further development and field implementation will improve our ability to detect emergent viral threats and ultimately limit their impact.</p>
<p align="right"><i>score: 132</i></p>

</div><br /><br /><br /><div class="card"><h3>Plasmonic silver nanoshells for drug and metabolite detection</h3>
<p style="text-align: justify; text-justify: inter-word;">In-vitro metabolite and drug detection rely on designed materials-based analytical platforms, which are universally used in biomedical research and clinical practice. However, metabolic analysis in bio-samples needs tedious sample preparation, due to the sample complexity and low molecular abundance. A further challenge is to construct diagnostic tools. Herein, we developed a platform using silver nanoshells. We synthesized SiO 2 @Ag with tunable shell structures by multi-cycled silver mirror reactions. Optimized nanoshells achieved direct laser desorption/ionization mass spectrometry in 0.5 Î¼L of bio-fluids. We applied these nanoshells for disease diagnosis and therapeutic evaluation. We identified patients with postoperative brain infection through daily monitoring and glucose quantitation in cerebrospinal fluid. We measured drug distribution in blood and cerebrospinal fluid systems and validated the function of blood-brain/cerebrospinal fluid-barriers for pharmacokinetics. Our work sheds light on the design of materials for advanced metabolic analysis and precision diagnostics.</p>
<p align="right"><i>score: 132</i></p>

</div><br /><br /><br /><div class="card"><h3>Moving pathogen genomics out of the lab and into the clinic: what will it take?</h3>
<p style="text-align: justify; text-justify: inter-word;">Pathogen genomic analysis is a potentially transformative new approach to the clinical and public-health management of infectious diseases. Health systems investing in this technology will need to build infrastructure and develop policies that ensure genomic information can be generated, shared and acted upon in a timely manner.</p>
<p align="right"><i>score: 131</i></p>

</div><br /><br /><br /><div class="card"><h3>Performance and workflow assessment of six nucleic acid extraction technologies for use in resource limited settings</h3>
<p style="text-align: justify; text-justify: inter-word;">Infectious disease nucleic acid amplification technologies (NAAT) have superior sensitivity, specificity, and rapid time to result compared to traditional microbiological methods. Recovery of concentrated, high quality pathogen nucleic acid (NA) from complex specimen matrices is required for optimal performance of several NA amplification/detection technologies such as polymerase chain reaction (PCR). Fully integrated NAAT platforms that enable rapid sample-to-result workflows with minimal user input are generally restricted to larger reference lab settings, and their complexity and cost are prohibitive to widespread implementation in resource limited settings (RLS). Identification of component technologies for incorporation of reliable and affordable sample preparation with pathogen NA amplification/ detection into an integrated platform suitable for RLS, is a necessary first step toward achieving the overarching goal of reducing infectious disease-associated morbidity and mortality globally. In the current study, we evaluate the performance of six novel NA extraction technologies from different developers using blinded panels of stool, sputum and blood spiked with variable amounts of quality-controlled DNA-and/or RNA-based microbes. The extraction efficiencies were semi-quantitatively assessed using validated real-time reverse transcription (RT)-PCR assays specific for each microbe and comparing target-specific RT-PCR results to those obtained with reference NA extraction methods. The technologies were ranked based on overall diagnostic accuracy (analytical sensitivity and specificity). Sample input and output volumes, total processing time, user-required manual steps and cost estimates were also examined for suitability in RLS. Together with the performance analysis, these metrics were used to select the more suitable candidate technologies for further optimization of integrated NA amplification and detection technologies for RLS.</p>
<p align="right"><i>score: 129</i></p>

</div><br /><br /><br /><div class="card"><h3>Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review</h3>
<p style="text-align: justify; text-justify: inter-word;">Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.</p>
<p align="right"><i>score: 128</i></p>

</div><br /><br /><br /><div class="card"><h3>Multiplex logic processing isothermal diagnostic assays for an evolving virus</h3>
<p style="text-align: justify; text-justify: inter-word;">The ease-of-use with minimal instrumentation, broad programmability, and built-in fail-safe reliability make our smart molecular diagnostic attractive for POC use.</p>
<p align="right"><i>score: 127</i></p>

</div><br /><br /><br /></body>